Le Lézard
Classified in: Health, Science and technology
Subject: FDA

FDA approves first oral GLP-1 treatment for type 2 diabetes


SILVER SPRING, Md., Sept. 20, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with type 2 diabetes, along with diet and exercise. Rybelsus is the first glucagon-like peptide (GLP-1) receptor protein treatment approved for use in the United States that does not need to be injected. GLP-1 drugs are non-insulin treatments for people with type 2 diabetes.

U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)

"Patients want effective treatment options for diabetes that are as minimally intrusive on their lives as possible, and the FDA welcomes the advancement of new therapeutic options that can make it easier for patients to control their condition," said Lisa Yanoff, M.D, acting director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research. "Before this approval, patients did not have an oral GLP1 option to treat their type 2 diabetes, and now patients will have a new option for treating type 2 diabetes without injections."

Type 2 diabetes is the most common form of diabetes, occurring when the pancreas cannot make enough insulin to keep blood sugar at normal levels. GLP-1, which is a normal body hormone, is often found in insufficient levels in type 2 diabetes patients. Like GLP-1, Rybelsus slows digestion, prevents the liver from making too much sugar, and helps the pancreas produce more insulin when needed.

The efficacy and safety of Rybelsus in reducing blood sugar in patients with type 2 diabetes were studied in several clinical trials, two of which were placebo-controlled and several of which were compared to other GLP-1 injection treatments. Rybelsus was studied as a stand-alone therapy and in combination with other diabetes treatments, including metformin, sulfonylureas (insulin secretagogues), sodium-glucose co-transporter-2 (SGLT-2) inhibitors, insulins and thiazolidinediones, all in patients with type 2 diabetes.

In the placebo-controlled studies, Rybelsus as a stand-alone therapy resulted in a significant reduction in blood sugar (hemoglobin A1c) compared with placebo, as determined through HbA1c tests, which measure average levels of blood sugar over time. After 26 weeks, 69% of those taking 7 mg once daily and 77% of those taking 14 mg once daily of Rybelsus decreased their HbA1c to lower than 7%, compared with 31% of patients on placebo.

The prescribing information for Rybelsus includes a boxed warning to advise health care professionals and patients about the potential increased risk of thyroid c-cell tumors, and that Rybelsus is not recommended as the first choice of medicine for treating diabetes. Patients who have ever had medullary thyroid carcinoma (MTC) or who have a family member who has ever had MTC are advised not to use Rybelsus. Additionally, patients who have ever had an endocrine system condition called multiple endocrine neoplasia syndrome type 2 (MEN 2) are advised not to use Rybelsus. Rybelsus is not for use in patients with type 1 diabetes and people with diabetic ketoacidosis.

Rybelsus also has warnings about pancreatitis (inflammation of the pancreas), diabetic retinopathy (damage to the eye's retina), hypoglycemia (low blood sugar), acute kidney injury and hypersensitivity reactions. It is not known whether Rybelsus can be used by patients who have had pancreatitis. The risk of hypoglycemia increased when Rybelsus was used in combination with sulfonylureas or insulin.

Rybelsus should be taken at least 30 minutes before the first food, beverage or other oral medication of the day, with no more than 4 ounces of plain water. Rybelsus slows digestion, so patients should discuss other medications they are taking with their health care provider before starting Rybelsus. The most common side effects are nausea, diarrhea, vomiting, decreased appetite, indigestion and constipation.

The approval of Rybelsus was granted to Novo Nordisk. 

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

Media Inquiries: Nathan Arnold, 301-796-6248, nathan.arnold@fda.hhs.gov
Consumer Inquiries: 888-INFO-FDA

SOURCE U.S. Food and Drug Administration


These press releases may also interest you

at 16:15
FINEOS Corporation , the market-leading provider of group and individual core systems for life, accident and health insurance, today announced that QInsure, the insurance arm of QSuper, one of Australia's largest and most respected superannuation...

at 16:05
CrowdStrike® Inc. , a leader in cloud-delivered endpoint protection, today announced Baidam Solutions has joined the CrowdStrike Elevate Partner Program. Through this strategic partnership, Baidam Solutions will combine their offerings with...

at 13:17
A new study of U.S. mobile consumers, conducted by Reach Mobile during October and November 2019, finds that 90% of consumers overpay for unlimited data plans. The report, which surveyed 400 U.S. consumers on major carrier unlimited plans, finds that...

at 12:00
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Pareteum Corporation from December 14, 2017 through October 21, 2019, inclusive (the "Class Period") of the important December 23, 2019 lead plaintiff deadline...

at 09:10
Compare-autoinsurance.org has released a new blog post that informs policyholders on how to make the auto insurance premiums cheaper. For more info and free car insurance quotes online, visit...

at 09:00
SpringboardVR, a leading content marketplace and distribution platform for VR Arcade operators and VRstudios, an innovator of turn-key wireless multiplayer Virtual Reality (VR) systems for Location-Based Entertainment (LBE) businesses, are pleased to...



News published on 20 september 2019 at 10:42 and distributed by: